Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04613245
Other study ID # Serial 39-2020
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 1, 2020
Est. completion date March 1, 2021

Study information

Verified date December 2020
Source Cairo University
Contact Youssef
Phone +201149495552
Email youssef_naglaa@cu.edu.eg
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Nowadays, the COVID-19 epidemic causes stress not only to healthy people but also to people with unhealthy conditions. Excess psychological stress (either in quality, quantity, frequency, and/or duration) could push susceptible individuals to ultimately develop clinical asthma. Depression was significantly associated with asthma interference with daily activities, breathlessness, night symptoms, use of bronchodilators, and poor compliance with medical treatment. Covid-19 pandemic induced the countries around the world to require from its citizens not to ask for health care support rather than in emergency situations and through utilizing telemedicine. This action aims to control spreading the infection with viruses as well as to reduce the workload on the healthcare providers. Although asthma is not listed as one of the chronic conditions that might complicate coronavirus infections, asthma people might have a high-stress level that might induce their asthma attack which consequentially reflects on their quality of life. People with asthma have a unique experience rather than people with other health conditions during COVID-19. Patients with asthma experience a lot of stressors that might induce asthma and impaired their HRQOL such as overuse of antiseptic substances, stay home with a sedentary lifestyle, the sudden shift to telemedicine, and electronic work from home. Also, as a result of the similarity of asthma symptoms with coronavirus symptoms, the patient might have a continuous sense of uncertainty that s/he is infected with the COVID-19 virus, and this suspicion can increase the psychological overburden on these patients. Therefore, all these stressors should be evaluated to recognize their health needs and the kind of social and health support that should be provided to them during the pandemic time. Also, Identifying the predictors of HRQOL among patients with asthma during the pandemic of COVID-19 is urgently required.


Description:

Asthma is a chronic inflammatory disease of the lower respiratory tract which derives from a combination of genetic predisposition with environmental exposure to several factors. It is a chronic respiratory disease that results in morbidity, mortality, and impaired health-related quality of life (HRQoL). It is estimated that 334 million people have asthma worldwide. Nowadays, the COVID-19 epidemic causes stress not only to healthy people but also to people with unhealthy conditions. Excess psychological stress (either in quality, quantity, frequency, and/or duration) could push susceptible individuals to ultimately develop clinical asthma. Depression was significantly associated with asthma interference with daily activities, breathlessness, night symptoms, use of bronchodilators, and poor compliance with medical treatment. Covid-19 pandemic induced the countries around the world to require from its citizens not to ask for health care support rather than in emergency situations and through utilizing telemedicine. This action aims to control spreading the infection with viruses as well as to reduce the workload on the healthcare providers. Although asthma is not listed as one of the chronic conditions that might complicate coronavirus infections, asthma people might have a high-stress level that might induce their asthma attack which consequentially reflects on their quality of life. People with asthma have a unique experience rather than people with other health conditions during COVID-19. Patients with asthma experience a lot of stressors that might induce asthma and impaired their HRQOL such as overuse of antiseptic substances, stay home with a sedentary lifestyle, the sudden shift to telemedicine, and electronic work from home. Also, as a result of the similarity of asthma symptoms with coronavirus symptoms, the patient might have a continuous sense of uncertainty that s/he is infected with the COVID-19 virus, and this suspicion can increase the psychological overburden on these patients. Therefore, all these stressors should be evaluated to recognize their health needs and the kind of social and health support that should be provided to them during the pandemic time. Also, Identifying the predictors of HRQOL among patients with asthma during the pandemic of COVID-19 is urgently required. A cross-sectional analytical design will be utilized. The study participants will be adults (18 years or older) who have been diagnosed with bronchial asthma or pulmonary disease.


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date March 1, 2021
Est. primary completion date January 30, 2021
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participant's age: 18 years or older - medically diagnosed with bronchial asthma Exclusion Criteria: - not medically diagnosed with asthma by a physician

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Egypt Egypt Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Asthma Control Questionnaire (ACQ) ACQ has a multidimensional construct assessing symptoms (5 items--self-administered) and rescue in bronchodilator use (1 item-self-administered), and FEV1% (1 item) completed by clinic staff, but it will not be applied in the current study as it will be difficult to be self-reported by the participants. 7-point scale (0=no impairment, 6= maximum impairment for symptoms. Scores range between 0 (totally controlled) and 6 (severely uncontrolled). One week
Secondary Mini Asthma Quality of Life Questionnaire The MiniAQLQ will be utilized to investigate the HRQoL of the participants. The Mini AQLQ-S has 15 questions that gives an overall summary index and four domains: activity limitation, symptoms, emotional function, and environmental stimuli. The questions all refer to the "last two weeks" and use seven Likert-type response options e.g., seven response options ranging from "all of the time" to "none of the time". two weeks
Secondary Perceived Stress Scale Perceived Stress Scale is a self-reported measure of the degree to which situations in an individual's life are perceived as stressful. PSS has 14 items can assess the degree to which individuals found their life unpredictable, uncontrollable, and overloaded. month
See also
  Status Clinical Trial Phase
Recruiting NCT02934945 - Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients Phase 4
Completed NCT02561351 - Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation N/A
Recruiting NCT01759472 - Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test N/A
Completed NCT01918293 - Self-Management Using Smartphone Application for Chronic Disease Care in Real siTuation (SMART-Asthma): Adult N/A
Completed NCT01203904 - Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation N/A
Completed NCT01762917 - Influence of Bag Volume Variation on the Reproducibility of Inert Gas Rebreathing N/A
Completed NCT00536731 - Symbicort Rapihaler Therapeutic Equivalence Study Phase 3
Completed NCT00331929 - Respiratory Health Study of Children in Kiryat Tivon N/A
Completed NCT00930826 - Childhood Asthma and Schooling: The Truth Unveiled N/A
Completed NCT00327028 - Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma Phase 4
Completed NCT00413387 - Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®) Phase 3
Completed NCT00153283 - Study of Efficacy of Gabapentin in Therapy of Bronchial Asthma Phase 4
Completed NCT00950794 - Study of Salmeterol (SN408D) for Adult Asthma Phase 4
Completed NCT00142025 - Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma Phase 4
Completed NCT00153270 - Study of Efficacy of Sodium Valproate in Therapy of Bronchial Asthma Phase 4
Completed NCT03450434 - XC8 in the Treatment of Patients With Bronchial Asthma Phase 2
Recruiting NCT05189613 - Mepolizumab Effectiveness in Severe Eosinophilic Asthma and Bronchiectasis N/A
Recruiting NCT04128111 - Study on the Correlation Between TCM Syndrome, Inflammatory Phenotype and Biomarker of Bronchial Asthma
Completed NCT06326632 - Comparative Effectiveness Study of Constant-Load Versus Graded Aerobic Exercise in Obese Children With Bronchial Asthma N/A
Completed NCT05088512 - The Role of Genetic Factors in the Development of Bronchial Asthma in the Kazakh Population